# Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS

> **NCT03151993** · PHASE3 · COMPLETED · sponsor: **Supergene, LLC** · enrollment: 336 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Recombinant staphylokinase
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT03151993
- **Lead sponsor:** Supergene, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-18
- **Primary completion:** 2019-03-23
- **Final completion:** 2019-06-20
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03151993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03151993, "Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03151993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*